BMY
Bristol-Myers Squibb Co.

20,478
Mkt Cap
$87.16B
Volume
16M
52W High
$63.33
52W Low
$42.75
PE Ratio
17.28
BMY Fundamentals
Price
$42.60
Prev Close
$42.82
Open
$42.82
50D MA
$45.58
Beta
0.30
Avg. Volume
14.55M
EPS (Annual)
-$4.41
P/B
5.00
Rev/Employee
$1.42M
Loading...
Loading...
News
all
press releases
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit
Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit As noted earlier, investors face a monumentally important and extremely busy week ahead that includes rates...
Zero Hedge·2d ago
News Placeholder
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
Zacks·2d ago
News Placeholder
Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Zacks·2d ago
News Placeholder
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
Bristol Myers Squibb (NYSE:BMY) today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active...
Business Wire·2d ago
News Placeholder
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its...
Business Wire·4d ago
News Placeholder
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
Zacks·5d ago
News Placeholder
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·6d ago

Latest BMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.